ECSP034798A - Amidas de acido benzofuran-2-carboxílico sustituidas - Google Patents

Amidas de acido benzofuran-2-carboxílico sustituidas

Info

Publication number
ECSP034798A
ECSP034798A EC2003004798A ECSP034798A ECSP034798A EC SP034798 A ECSP034798 A EC SP034798A EC 2003004798 A EC2003004798 A EC 2003004798A EC SP034798 A ECSP034798 A EC SP034798A EC SP034798 A ECSP034798 A EC SP034798A
Authority
EC
Ecuador
Prior art keywords
diseases
treatment
cerebral
disorders
amidas
Prior art date
Application number
EC2003004798A
Other languages
English (en)
Inventor
Dieter Dorsch
Gerd Bartoszyk
Henning Boettcher
Amsterdam Christoph Van
Wilfried Rautenberg
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP034798A publication Critical patent/ECSP034798A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

donde D, R1, R2 y n tienen los significados mencionados en la reivindicación 1, son potentes agonistas de 5-HT1A e inhibidores de la reabsorción de 5-HT y son apropiados para el tratamiento de depresiones, estados de angustia, ataques de pánico, trastornos obsesivos enfermedades psiquiátricas, infartos cerebrales, isquemia cerebral, estados de ansiedad, de efectos secundarios del tratamiento de la hipertensión sanguínea, para la prevención y el tratamiento de enfermedades cerebrales, acromegalia, hipogonadismo, amenorrea secundaria, síndrome premenstrual, lactancia puerperal no deseada, dolor, trastornos del sueño, narcolepsia, enfermedades bipolares, manías, demencia, enfermedades adictivas, disfunciones sexuales, trastornos de la alimentación, obesidad o fibromialgia.
EC2003004798A 2001-03-14 2003-10-09 Amidas de acido benzofuran-2-carboxílico sustituidas ECSP034798A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10112151A DE10112151A1 (de) 2001-03-14 2001-03-14 Substituierte Benzofuran-2-carbonsäureamide

Publications (1)

Publication Number Publication Date
ECSP034798A true ECSP034798A (es) 2003-12-01

Family

ID=7677358

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004798A ECSP034798A (es) 2001-03-14 2003-10-09 Amidas de acido benzofuran-2-carboxílico sustituidas

Country Status (20)

Country Link
US (1) US7244846B2 (es)
EP (1) EP1368346A1 (es)
JP (1) JP4485743B2 (es)
KR (1) KR20030080083A (es)
CN (1) CN1244578C (es)
AR (1) AR035782A1 (es)
BR (1) BR0208040A (es)
CA (1) CA2440726C (es)
CZ (1) CZ20032712A3 (es)
DE (1) DE10112151A1 (es)
EC (1) ECSP034798A (es)
EE (1) EE200300447A (es)
HU (1) HUP0303449A3 (es)
IL (1) IL157889A0 (es)
MX (1) MXPA03008140A (es)
PL (1) PL362844A1 (es)
RU (1) RU2003129057A (es)
SK (1) SK12492003A3 (es)
WO (1) WO2002083666A1 (es)
ZA (1) ZA200307966B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259244A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
DE10305739A1 (de) * 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
DE10306941A1 (de) * 2003-02-18 2004-08-26 Merck Patent Gmbh Benzofuranoxyethylamine
DE10326940A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
DE10326939A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
DE102005019670A1 (de) * 2005-04-26 2006-11-02 Merck Patent Gmbh Verfahren zur Herstellung von (5-(4-[4-(5-Cyano-3-indolyl)-butyl)-1-piperazinyl)-benzofuran-2-carboxamid
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
DE102006060597A1 (de) 2006-12-21 2008-06-26 Merck Patent Gmbh Verfahren zur Herstellung von Benzofuran-2-carboxamiden
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
CN101970436A (zh) * 2008-03-14 2011-02-09 默克专利股份有限公司 用于治疗中枢神经系统功能障碍的氮杂吲哚化合物
EP2110374A1 (en) * 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
KR101361145B1 (ko) * 2011-03-10 2014-02-12 한국화학연구원 신규한 벤조퓨란-2-카르복사미드 유도체 및 그의 ｍｃｈ 수용체-1 관련 질환에 대한 치료학적 용도
CN103570698B (zh) * 2012-08-01 2016-08-03 江苏恩华药业股份有限公司 用于制备维拉佐酮的化合物及其中间体和应用
WO2015014256A1 (en) 2013-07-29 2015-02-05 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof
US10316025B2 (en) 2015-06-03 2019-06-11 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4333254A1 (de) 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
DE19730989A1 (de) 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders

Also Published As

Publication number Publication date
HUP0303449A2 (hu) 2004-01-28
IL157889A0 (en) 2004-03-28
SK12492003A3 (sk) 2004-03-02
CN1244578C (zh) 2006-03-08
EE200300447A (et) 2003-12-15
PL362844A1 (en) 2004-11-02
AR035782A1 (es) 2004-07-14
KR20030080083A (ko) 2003-10-10
RU2003129057A (ru) 2005-04-10
DE10112151A1 (de) 2002-09-19
MXPA03008140A (es) 2003-12-12
CA2440726C (en) 2011-05-17
WO2002083666A1 (en) 2002-10-24
EP1368346A1 (en) 2003-12-10
HUP0303449A3 (en) 2005-02-28
CZ20032712A3 (cs) 2004-01-14
BR0208040A (pt) 2004-02-25
CN1494543A (zh) 2004-05-05
US7244846B2 (en) 2007-07-17
ZA200307966B (en) 2005-01-13
JP4485743B2 (ja) 2010-06-23
US20050075269A1 (en) 2005-04-07
JP2004527536A (ja) 2004-09-09
CA2440726A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
ECSP034798A (es) Amidas de acido benzofuran-2-carboxílico sustituidas
NO20052591D0 (no) Pyridopyrolizin og pyridoindolizinderivater
BG108207A (en) Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
MXPA04003858A (es) Antagonistas de mch para el tratamiento de obesidad.
MX2007001986A (es) Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
NO20054200L (no) Pyrazoler samt fremgangsmate for fremstilling derav
CY1111138T1 (el) Πυραζολο-υποκατεστημενες αμινοετεροαρυλ ενωσεις ως αναστολεις κινασης πρωτεϊνης
CY1106011T1 (el) Χρηση αναστολεων κινασης τυροσινης για την αγωγη αλλepγικων παθησεων
WO2001079169A3 (en) Prostaglandin d2 receptor antagonists
WO2003045918A8 (en) Piperidine-based mch antagonists for treatment of obesity and cns disorders
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
DE602004024900D1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20051503L (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
WO2001045730A3 (en) Tweak receptor
NO20071343L (no) Substituerte fenylaminotiazoler og anvendelse derav
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
CY1105930T1 (el) Χρηση αναστολεων c-kit για θepαπεια ασθενειων φλεγμονωδους εντερου (ibd)
EP1254662A3 (en) Methods and kits for treating depression or preventing deterioration of cognitive function
DK1747220T3 (da) Substituerede 1H-pyrrolo[3,2-B, 3,2-C og 2,3-C]pyridin-2-carboxamider og relaterede analoger som inhibitorer af casein kinase I epsilon
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
PA8540101A1 (es) Metodo para el tratamiento de enfermedades o condiciones por desmielinizacion
NO20055741L (no) Nye kjemiske forbindelser